ASCO puts spotlight on advancing antibody-drug conjugate pipeline

The past several years have brought about a revival in the development of a complex, but powerful type of cancer treatment. Known as antibody-drug conjugates, or ADCs, these therapies have newly become a must-have asset for pharmaceutical companies serious about oncology research — a shift from much of the past two decades.